$GNPX
Genprex Inc

2019 Q4 Form 10-K Financial Statement

#000143774921007317 Filed on March 26, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.930M $8.700M $3.120M
YoY Change -38.14% -23.62% 420.0%
% of Gross Profit
Research & Development $490.0K $1.967M $320.0K
YoY Change 53.13% 102.49% 433.33%
% of Gross Profit
Depreciation & Amortization $0.00 $13.07K $10.00K
YoY Change -100.0% 122.09%
% of Gross Profit
Operating Expenses $2.430M $1.967M $3.440M
YoY Change -29.36% 102.49% 421.21%
Operating Profit -$10.68M
YoY Change -13.6%
Interest Expense $0.00 $10.00K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.420M -$10.65M -$3.430M
YoY Change -29.45% -13.9% 411.94%
Income Tax
% Of Pretax Income
Net Earnings -$2.420M -$10.65M -$3.430M
YoY Change -29.45% -13.88% 411.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$139.8K -$664.4K -$227.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.000M $2.000M $8.600M
YoY Change -76.74% -76.74% 5275.0%
Cash & Equivalents $2.002M $8.601M
Short-Term Investments
Other Short-Term Assets $170.0K $170.0K $240.0K
YoY Change -29.17% -29.17% 1100.0%
Inventory $800.0K $800.0K
Prepaid Expenses
Receivables $0.00 $0.00 $10.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.977M $2.980M $8.847M
YoY Change -66.35% -66.33% 4470.38%
LONG-TERM ASSETS
Property, Plant & Equipment $44.65K $40.00K $24.35K
YoY Change 83.35% 100.0% 212.07%
Goodwill
YoY Change
Intangibles $491.2K $379.5K
YoY Change 29.45% 27.09%
Long-Term Investments
YoY Change
Other Assets $512.9K $20.00K $397.5K
YoY Change 29.03% 0.0% -62.43%
Total Long-Term Assets $557.6K $550.0K $421.9K
YoY Change 32.16% 30.95% -60.42%
TOTAL ASSETS
Total Short-Term Assets $2.977M $2.980M $8.847M
Total Long-Term Assets $557.6K $550.0K $421.9K
Total Assets $3.534M $3.530M $9.269M
YoY Change -61.87% -61.92% 635.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $440.0K $440.0K $300.0K
YoY Change 46.67% 46.67% -52.38%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $70.00K $70.00K $90.00K
YoY Change -22.22% -22.22% -55.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $510.7K $510.0K $387.8K
YoY Change 31.68% 30.77% -53.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $510.7K $510.0K $387.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $510.0K $510.0K $390.0K
YoY Change 30.77% 30.77% -53.01%
SHAREHOLDERS EQUITY
Retained Earnings -$40.48M -$29.82M
YoY Change 35.72% 70.89%
Common Stock $19.26K $15.24K
YoY Change 26.4% 30.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.024M $3.020M $8.881M
YoY Change
Total Liabilities & Shareholders Equity $3.534M $3.530M $9.269M
YoY Change -61.87% -61.92% 635.9%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$2.420M -$10.65M -$3.430M
YoY Change -29.45% -13.88% 411.94%
Depreciation, Depletion And Amortization $0.00 $13.07K $10.00K
YoY Change -100.0% 122.09%
Cash From Operating Activities -$1.720M -$6.919M -$2.070M
YoY Change -16.91% 1.05% 885.71%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $33.37K -$60.00K
YoY Change 66.67% 48.74%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$800.0K
YoY Change
Cash From Investing Activities -$90.00K -$946.9K -$60.00K
YoY Change 50.0% 816.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.267M
YoY Change -91.77%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.270M 1.267M 420.0K
YoY Change 202.38% -91.77%
NET CHANGE
Cash From Operating Activities -1.720M -6.919M -2.070M
Cash From Investing Activities -90.00K -946.9K -60.00K
Cash From Financing Activities 1.270M 1.267M 420.0K
Net Change In Cash -540.0K -6.598M -1.710M
YoY Change -68.42% -178.18% 714.29%
FREE CASH FLOW
Cash From Operating Activities -$1.720M -$6.919M -$2.070M
Capital Expenditures -$100.0K $33.37K -$60.00K
Free Cash Flow -$1.620M -$6.952M -$2.010M
YoY Change -19.4% 1.21% 857.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
601625
CY2018Q1 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2019 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
44528
CY2019 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0.50
CY2020Q4 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
1904747
CY2020Q4 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
4.61
CY2019 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2020 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
5826781
CY2019 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2020 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.47
CY2019 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0.47
CY2020 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
2.41
CY2019 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3611504
CY2020 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
550000
CY2020Q4 gnpx Investment Unit
InvestmentUnit
0
CY2019Q4 gnpx Investment Unit
InvestmentUnit
0
CY2019 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
1267194
CY2020 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
41589529
CY2018Q2 gnpx Nonvoting To Voting Common Stock Conversion Ratio
NonvotingToVotingCommonStockConversionRatio
1
CY2018Q2 gnpx Operating Lease Rent Expense Per Month
OperatingLeaseRentExpensePerMonth
462
CY2020 gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
2209262
CY2019 gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
801780
CY2010 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2011 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2020Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3011042
CY2019Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
801780
CY2010Q4 gnpx State Of Texas Emerging Technology Fund Award Amount
StateOfTexasEmergingTechnologyFundAwardAmount
4500000
CY2020 gnpx Stock Cancelled During Period Shares
StockCancelledDuringPeriodShares
44528
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2013Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2500000
CY2020 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
199630
CY2020 gnpx Stock Issued During Period Shares Warrants Issued
StockIssuedDuringPeriodSharesWarrantsIssued
5511599
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
192968
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
436258
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89295601
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43483740
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3060396
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4091538
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3500000
CY2020Q4 us-gaap Assets
Assets
31367214
CY2019Q4 us-gaap Assets
Assets
3534229
CY2020Q4 us-gaap Assets Current
AssetsCurrent
30715407
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2976643
CY2020Q4 us-gaap Cash
Cash
27319685
CY2019Q4 us-gaap Cash
Cash
2002492
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2002492
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8600918
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27319685
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25317193
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6598426
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
27091596
CY2019Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1761278
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.36
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.45
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.37
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
315182
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3864552
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7476056
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2154747
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43117681
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19263841
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43117681
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19263841
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
43118
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
19264
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
17961581
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
10682673
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21732
CY2020 us-gaap Depreciation
Depreciation
22777
CY2019 us-gaap Depreciation
Depreciation
13070
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
491200
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10635881
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8702596
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-247290
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
141189
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-528
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8642
CY2020 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-10991
CY2019 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
3647
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
187329
CY2019 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-18326
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
212837
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-65135
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
18811
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
510684
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41589529
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
27905
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31367214
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3534229
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
450724
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1267194
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2337250
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-946899
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13935086
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6918721
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17942770
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-10654768
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-17961581
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-10682673
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
44600000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
612366
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
512932
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
257756
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74426
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
110424
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
111749
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17564
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33370
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
384553
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
171716
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41589529
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1267194
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2537731
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39441
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44654
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.31
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
127
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
655
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7302923
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1967007
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58422229
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40479459
CY2020 us-gaap Revenues
Revenues
CY2019 us-gaap Revenues
Revenues
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4246186
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3529984
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4491545
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.75
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
297058
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
327640
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
327640
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
297058
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1744300
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6844069
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4535681
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5982923
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.31
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.03
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.48
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.87
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y21D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y164D
CY2020 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
51432
CY2019 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
506707
CY2020 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5511599
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
154648
CY2019 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
469588
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2537731
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1320155
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30916490
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3023545
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8881135
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6.6841954
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35522875
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16026980

Files In Submission

Name View Source Status
0001437749-21-007317-index-headers.html Edgar Link pending
0001437749-21-007317-index.html Edgar Link pending
0001437749-21-007317.txt Edgar Link pending
0001437749-21-007317-xbrl.zip Edgar Link pending
ex_220400.htm Edgar Link pending
ex_220401.htm Edgar Link pending
ex_220402.htm Edgar Link pending
ex_236118.htm Edgar Link pending
ex_236832.htm Edgar Link pending
ex_236861.htm Edgar Link pending
ex_236864.htm Edgar Link pending
ex_237224.htm Edgar Link pending
ex_237225.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-20201231.xml Edgar Link completed
gnpx-20201231.xsd Edgar Link pending
gnpx-20201231_cal.xml Edgar Link unprocessable
gnpx-20201231_def.xml Edgar Link unprocessable
gnpx-20201231_lab.xml Edgar Link unprocessable
gnpx-20201231_pre.xml Edgar Link unprocessable
gnpx20201231_10k.htm Edgar Link pending
gpx002_800.jpg Edgar Link pending
gylze0pdymuz000002.jpg Edgar Link pending
gylze0pdymuz000003.jpg Edgar Link pending
gylze0pdymuz000004.jpg Edgar Link pending
gylze0pdymuz000005.jpg Edgar Link pending
gylze0pdymuz000006.jpg Edgar Link pending
gylze0pdymuz000010.jpg Edgar Link pending
gylze0pdymuz000011.jpg Edgar Link pending
gylze0pdymuz000012.jpg Edgar Link pending
pipeline_v10.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
reqorsatarcevacombo_800.jpg Edgar Link pending
reqorsa_synergisticimage1.jpg Edgar Link pending
reqorsa_synergisticimage2.jpg Edgar Link pending
Show.js Edgar Link pending